flow trial semaglutide kidney outcomes hazard ratio 0.76 The rationale, design and baseline data of FLOW, a with once-weekly in people with type 2 diabetes and chronic kidney disease Preventing chronic kidney disease and

The lesson here is simple: If you are offering GLP-1s, your sourcing, documentation, consent forms, and marketing language all need to line up

Crucial for keratin production

Nat Rev Endocrinol 14:390403 Ansari MN, Rehman NU, Karim A, Soliman GA, Ganaie MA, Raish M, Hamad AM (2021) Role of oxidative stress and inflammatory cytokines (Tnf- and il-6) in acetic acid-induced ulcerative colitis in rats: ameliorated by otostegia fruticosa

These insights can support more informed conversations between you and your prescriber about whether GLP-1 therapy aligns with your genetic pathway profilethough genetic predisposition does not predict exact medication response